Literature DB >> 30610858

An Interactive Web-Based Educational Tool Improves Detection and Delineation of Barrett's Esophagus-Related Neoplasia.

Jacques J G H M Bergman1, A Jeroen de Groof2, O Pech3, K Ragunath4, D Armstrong5, N Mostafavi6, L Lundell7, J Dent8, M Vieth9, G N Tytgat2, P Sharma10.   

Abstract

BACKGROUND & AIMS: Endoscopic detection of early Barrett's esophagus-related neoplasia (BORN) is a challenge. We aimed to develop a web-based teaching tool for improving detection and delineation of BORN.
METHODS: We made high-definition digital videos during endoscopies of patients with BORN and non-dysplastic Barrett's esophagus. Three experts superimposed their delineations of BORN lesions on the videos using special tools. In phase one, 68 general endoscopists from 4 countries assessed 4 batches of 20 videos. After each batch, mandatory feedback compared the assessors' interpretations with those from experts. These data informed the selection of 25 videos for the phase 2 module, which was completed by 121 new assessors from 5 countries. A 5-video test batch was completed before and after scoring of the four 5-video training batches. Mandatory feedback was as in phase 1. Outcome measures were scores for detection, delineation, agreement delineation, and relative delineation of BORN.
RESULTS: A linear mixed-effect model showed significant sequential improvement for all 4 outcomes over successive training batches in both phases. In phase 2, median detection rates of BORN in the test batch increased by 30% (P < .001) after training. From baseline to the end of the study, there were relative increases in scores of 46% for detection, 129% for delineation, 105% for agreement delineation, and 106% for relative delineation (all, P < .001). Scores improved independent of assessors' country of origin or level of endoscopic experience.
CONCLUSIONS: We developed a web-based teaching tool for endoscopic recognition of BORN that is easily accessible, efficient, and increases detection and delineation of neoplastic lesions. Widespread use of this tool might improve management of Barrett's esophagus by general endoscopists.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barrett Esophagus; Endoscopy; Esophageal Adenocarcinoma; The BORN Project

Mesh:

Year:  2019        PMID: 30610858     DOI: 10.1053/j.gastro.2018.12.021

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

Review 1.  Screening and Prevention of Barrett's Esophagus.

Authors:  Oliver Pech
Journal:  Visc Med       Date:  2019-07-25

2.  Post-endoscopy Esophageal Neoplasia in Barrett's Esophagus: Consensus Statements From an International Expert Panel.

Authors:  Sachin Wani; Rena Yadlapati; Siddharth Singh; Tarek Sawas; David A Katzka
Journal:  Gastroenterology       Date:  2021-10-14       Impact factor: 22.682

3.  What is the optimal surveillance strategy for non-dysplastic Barrett's esophagus?

Authors:  Ying Gibbens; Prasad G Iyer
Journal:  Curr Treat Options Gastroenterol       Date:  2020-06-25

4.  The Impact of Artificial Intelligence in the Endoscopic Assessment of Premalignant and Malignant Esophageal Lesions: Present and Future.

Authors:  Daniela Cornelia Lazăr; Mihaela Flavia Avram; Alexandra Corina Faur; Adrian Goldiş; Ioan Romoşan; Sorina Tăban; Mărioara Cornianu
Journal:  Medicina (Kaunas)       Date:  2020-07-21       Impact factor: 2.430

5.  Multicenter study on the diagnostic performance of multiframe volumetric laser endomicroscopy targets for Barrett's esophagus neoplasia with histopathology correlation.

Authors:  M R Struyvenberg; A J de Groof; A Kahn; B L A M Weusten; D E Fleischer; E K Ganguly; V J A Konda; C J Lightdale; D K Pleskow; A Sethi; M S Smith; A J Trindade; M B Wallace; H C Wolfsen; G J Tearney; S L Meijer; C L Leggett; J J G H M Bergman; W L Curvers
Journal:  Dis Esophagus       Date:  2020-12-07       Impact factor: 3.429

6.  JAG consensus statements for training and certification in oesophagogastroduodenoscopy.

Authors:  Keith Siau; Ian L P Beales; Adam Haycock; Durayd Alzoubaidi; Rachael Follows; Rehan Haidry; Jayan Mannath; Susan McConnell; Aravinth Murugananthan; Srivathsan Ravindran; Stuart A Riley; R N Williams; Nigel John Trudgill; Andrew M Veitch
Journal:  Frontline Gastroenterol       Date:  2022-01-24

Review 7.  Developing patient-orientated Barrett's oesophagus services: the role of dedicated services.

Authors:  Elizabeth Ratcliffe; James Britton; Shaheen Hamdy; John McLaughlin; Yeng Ang
Journal:  BMJ Open Gastroenterol       Date:  2022-02

Review 8.  Machine learning in GI endoscopy: practical guidance in how to interpret a novel field.

Authors:  Fons van der Sommen; Jeroen de Groof; Maarten Struyvenberg; Joost van der Putten; Tim Boers; Kiki Fockens; Erik J Schoon; Wouter Curvers; Peter de With; Yuichi Mori; Michael Byrne; Jacques J G H M Bergman
Journal:  Gut       Date:  2020-05-11       Impact factor: 23.059

9.  Endoscopic Resection Without Subsequent Ablation Therapy for Early Barrett's Neoplasia: Endoscopic Findings and Long-Term Mortality.

Authors:  S N van Munster; E A Nieuwenhuis; B L A M Weusten; L Alvarez Herrero; A Bogte; A Alkhalaf; B E Schenk; E J Schoon; W Curvers; A D Koch; S E M van de Ven; P J F de Jonge; T Tang; W B Nagengast; F T M Peters; J Westerhof; M H M G Houben; Jacques J G H M Bergman; R E Pouw
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

10.  Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.

Authors:  Sanne van Munster; Esther Nieuwenhuis; Bas L A M Weusten; Lorenza Alvarez Herrero; Auke Bogte; Alaa Alkhalaf; B E Schenk; Erik J Schoon; Wouter Curvers; Arjun D Koch; Steffi Elisabeth Maria van de Ven; Pieter Jan Floris de Jonge; Tjon J Tang; Wouter B Nagengast; Frans T M Peters; Jessie Westerhof; Martin H M G Houben; Jacques Jghm Bergman; Roos E Pouw
Journal:  Gut       Date:  2021-03-22       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.